Hikma to acquire Egyptian drug co for $2.2 mln

By Admin
Manufacturer of branded and non-branded generic and in-licensed pharmaceutical products Hikma Pharmaceuticals Plc has agreed to acquire Egyptian Compan...

Manufacturer of branded and non-branded generic and in-licensed pharmaceutical products Hikma Pharmaceuticals Plc has agreed to acquire Egyptian Company for Pharmaceuticals & Chemical Industries for $22.2 million in cash to strengthen its position in the Egyptian market.

The acquisition of EPCI will add a portfolio of 35 products in 46 dosages and strengths including three cephaslosporin anti-infection brands for the local market.

The global drug maker expects to complete the purchase before Feb 14. 

Said Darwazah, Hikma CEO, said, “Since we entered the Egyptian market in 2007, we have been rapidly growing our presence.” Mr. Darwazah also said, “This acquisition will further accelerate that growth.” Hikma said, the drug market of Egypt is one of the largest and fastest growing markets in the Middle East and North Africa.

The private retail market is worth about $2.3 billion and grew by 11% in 12 months to June 2012. 

Analysts James Vane Tempest and Peter Welford of Jefferies International Ltd said, the acquisition improves Hikma’s long-term prospects in the region, and should further boost investor confidence that Hikma can deliver on its acquisition strategy.

Cairo-based HC Securities & Investment acted as adviser to Hikma on the deal.

Hikma Pharmaceuticals is a multinational pharmaceutical company based in London. It manufactures branded and non-branded generic and in-licensed pharmaceutical products. The company was first listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Hikma was founded in Amman, Jordan in 1978 by its current Chairman, Mr. Samih Darwaza.

Share
Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals